Overview
- Researchers at the University of Cambridge built a connected brain–spinal cord organoid system that formed corticospinal-like circuits and even drove tiny muscle-cluster contractions in the dish.
- The team found a clear developmental window: axons regrew after injury up to about day 150 in culture but lost that capacity as the neurons matured.
- Gene-expression analysis identified a network that acts as a maturation 'switch' restricting axon growth, and blocking key regulators of that network restored axon regrowth in the model.
- A drug-screen flagged the hormone drug lynestrenol as a candidate that boosted regrowth in the organoid system, but the authors stress lynestrenol is an experimental lead that has not been tested in animals or humans for spinal repair.
- The work provides a human-specific proof of principle for targeting neuron-intrinsic limits to regeneration, yet major translational steps remain, including proving correct functional reconnection, testing safety and efficacy in vivo, and addressing injury-site factors such as scarring and inflammation.